JP2015512418A - うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 - Google Patents

うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 Download PDF

Info

Publication number
JP2015512418A
JP2015512418A JP2015503627A JP2015503627A JP2015512418A JP 2015512418 A JP2015512418 A JP 2015512418A JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015512418 A JP2015512418 A JP 2015512418A
Authority
JP
Japan
Prior art keywords
ketamine
scopolamine
administered
disorder
mcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512418A5 (cg-RX-API-DMAC7.html
Inventor
マウリツィオ ファバ
マウリツィオ ファバ
トレイシー ペトリシェン
トレイシー ペトリシェン
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2015512418A publication Critical patent/JP2015512418A/ja
Publication of JP2015512418A5 publication Critical patent/JP2015512418A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015503627A 2012-03-30 2013-03-29 うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 Pending JP2015512418A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618212P 2012-03-30 2012-03-30
US61/618,212 2012-03-30
PCT/US2013/034524 WO2013149102A1 (en) 2012-03-30 2013-03-29 Compositions comprising scopolamine and ketamine in the treatment of depression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018136350A Division JP2018184440A (ja) 2012-03-30 2018-07-20 うつ病の治療におけるスコポラミンおよびケタミンを含む組成物

Publications (2)

Publication Number Publication Date
JP2015512418A true JP2015512418A (ja) 2015-04-27
JP2015512418A5 JP2015512418A5 (cg-RX-API-DMAC7.html) 2015-06-11

Family

ID=49261273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503627A Pending JP2015512418A (ja) 2012-03-30 2013-03-29 うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
JP2018136350A Pending JP2018184440A (ja) 2012-03-30 2018-07-20 うつ病の治療におけるスコポラミンおよびケタミンを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018136350A Pending JP2018184440A (ja) 2012-03-30 2018-07-20 うつ病の治療におけるスコポラミンおよびケタミンを含む組成物

Country Status (4)

Country Link
US (2) US20150057306A1 (cg-RX-API-DMAC7.html)
EP (1) EP2830604A4 (cg-RX-API-DMAC7.html)
JP (2) JP2015512418A (cg-RX-API-DMAC7.html)
WO (1) WO2013149102A1 (cg-RX-API-DMAC7.html)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515557A (ja) * 2015-05-20 2018-06-14 ヤンセン ファーマシューティカ エヌ．ベー． うつ病を治療するための方法及びキット
US10744094B2 (en) 2017-10-10 2020-08-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11173134B2 (en) 2014-09-15 2021-11-16 Janssen Pharmaceutica Nv Methods for the treatment of depression
JP2022533971A (ja) * 2019-05-15 2022-07-27 ベクソン バイオメディカル，インク． 皮下注射のためのケタミン製剤
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US11883526B2 (en) 2019-03-05 2024-01-30 Janssen Pharmaceutica Nv Esketamine for the treatment of depression
US11980596B2 (en) 2017-09-13 2024-05-14 Janssen Pharmaceutica Nv Delivery of esketamine for the treatment of depression
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643449A (zh) 2013-03-15 2020-09-11 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
JP6845162B2 (ja) 2015-06-27 2021-03-17 シェノックス・ファーマシューティカルズ・エルエルシー ケタミン経皮送達システム
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US20200384188A1 (en) * 2017-11-14 2020-12-10 Bexson Biomedical, Inc. Systems, devices, formulations and methods for controlled drug delivery
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
US12005142B2 (en) * 2018-08-02 2024-06-11 Taiwan Liposome Co., Ltd. Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
US20230256004A1 (en) * 2020-07-09 2023-08-17 Light Aqua Llc Compositions and methods for treating mood disorders and circadian rhythm sleep disorders
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS
US20240050502A1 (en) * 2020-12-16 2024-02-15 Caamtech, Inc. Amanita muscaria compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1096196A (zh) * 1993-06-07 1994-12-14 李举寿 毒瘾戒断注射液及其制造方法
US20060270698A1 (en) * 2005-05-25 2006-11-30 Furey Maura L Scopolamine for the treatment of depression and anxiety
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1096196A (zh) * 1993-06-07 1994-12-14 李举寿 毒瘾戒断注射液及其制造方法
US20060270698A1 (en) * 2005-05-25 2006-11-30 Furey Maura L Scopolamine for the treatment of depression and anxiety
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DA-HAI, TAN ET AL.: "Scopolamine and ketamine produce interaction on the contents of AchE and expression of NR2B mRNA in", ZHONGHUA XINGWEI YIXUE YU NAOKEXUE ZAZHI, （CHIN. J. BEHAV. MED. AND BRAIN SCI.）, vol. 18, no. 11, JPN7016003285, November 2009 (2009-11-01), CN, pages 982 - 984, ISSN: 0003432010 *
DREVETS, W. C. ET AL.: "Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, pla", BIOLOGICAL PSYCHIATRY, vol. 67, no. 5, JPN6016042126, 1 March 2010 (2010-03-01), pages 432 - 438, ISSN: 0003432011 *
UCHIHASHI, YOSHITAKA ET AL.: "Assessment of the Ambulation-Increasing Effect of Ketamine by Coadministration with Central-Acting D", JAPAN JOURNAL OF PHARMACOLOGY, vol. 60, no. 1, JPN7016003284, 1992, JP, pages 25 - 31, ISSN: 0003432009 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311500B2 (en) 2014-09-15 2022-04-26 Janssen Pharmaceutica Nv Methods for the treatment of depression
US11173134B2 (en) 2014-09-15 2021-11-16 Janssen Pharmaceutica Nv Methods for the treatment of depression
JP2018515557A (ja) * 2015-05-20 2018-06-14 ヤンセン ファーマシューティカ エヌ．ベー． うつ病を治療するための方法及びキット
US11980596B2 (en) 2017-09-13 2024-05-14 Janssen Pharmaceutica Nv Delivery of esketamine for the treatment of depression
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471416B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US10744094B2 (en) 2017-10-10 2020-08-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US11883526B2 (en) 2019-03-05 2024-01-30 Janssen Pharmaceutica Nv Esketamine for the treatment of depression
JP2022533971A (ja) * 2019-05-15 2022-07-27 ベクソン バイオメディカル，インク． 皮下注射のためのケタミン製剤
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders

Also Published As

Publication number Publication date
US20170042878A1 (en) 2017-02-16
EP2830604A1 (en) 2015-02-04
EP2830604A4 (en) 2015-08-19
WO2013149102A1 (en) 2013-10-03
US20150057306A1 (en) 2015-02-26
JP2018184440A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US6335021B1 (en) Composition for controlling mood disorders in healthy individuals
US20190255027A1 (en) Methods of treating developmental disorders with gaboxadol
US20230201224A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20080021074A1 (en) Pharmaceutical Compositions and Related Methods of Treatment
US20080249082A1 (en) Use of Memantine (Namenda) to Treat Autism, Compulsivity and Impulsivity
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
KR20140041457A (ko) 신경 장애 치료용 신규 조성물
ES2991605T3 (es) Composiciones para el tratamiento de los trastornos relacionados con el estrés
CA2442330A1 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
CA3153305A1 (en) Methods for treating neurological disorders with ?1a-ar partial agonists
TW201424729A (zh) 用於治療創傷後壓力症候群之方法
KR20200018485A (ko) 우울 장애들의 치료
CN107835695A (zh) 用于治疗自闭症的组合物和方法
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
CN101610760B (zh) （s）-心得乐在制备治疗恶病质的药物中的用途
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
JP3916563B2 (ja) Ｐ物質の投与を含む治療方法
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
JP2010500377A (ja) 線維筋痛症に関わる認知機能障害を治療するためのミルナシプラン
JP2010500379A (ja) 線維筋痛症候群に関わる疲労を治療するためのミルナシプラン
JP2020525548A (ja) 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
TW202448421A (zh) 減少帕金森氏症之症狀的方法及組合物
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150410

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160107

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180328